Connect with us


Focus on this 61-year old pharmacy company and its looming 2018 loss 

The company specialises in the manufacturing and merchandising of drugs, both for human and animal consumption.



Neimeth International Pharmaceutical Plc

On this week’s Nairametrics company focus, we are back to profiling little-known companies whose stocks are listed on the Nigerian Stock Exchange (NSE). As you most likely already know, the purpose of this column is to spotlight some of the smaller securities that are seldom in the news. A typical example of such is Neimeth International Pharmaceutical Plc. Get to know everything about the company’s business model, history, its owners, competitors, financial records, growth prospects and more.

About Neimeth International Pharmaceuticals Plc: what they do 

With its headquarters in Lagos, Nigeria, Neimeth International Pharmaceuticals Plc specialises in the manufacturing and merchandising of drugs, both for human and animal consumption. The company’s pharmaceutical products, which come in various forms such as capsules, injectable drugs, ointments, liquids, and tablets, are marketed across Nigeria and much of the ECOWAS region.

A historical background of the company

Originally known as Pfizer Products Plc, this company began operation in Lagos, Nigeria as a drugstore back in 1957. It is one of the foremost pharmacy companies in the country and is said to have built the very first drug manufacturing plant in Nigeria. The plant, which was in Aba South-Eastern Nigeria, was later damaged during the three-year war that ravaged Aba and other cities and villages around it.

Pfizer Products Plc’s parent company was the American drug maker, Pfizer Inc, which in 1997 decided to divest 60% of its shareholdings in the former Nigerian subsidiary, in line with its refocused global business operation. The divestment saw a 60% buy-out of the parent company’s shareholding by the management of Pfizer Products Plc, led by the Mazi Sam I. Ohuabunwa, the company’s former CEO.

Following the change in ownership structure, a name change became necessary. Consequently, Pfizer Products Plc changed to Neimeth International Pharmaceutical Plc in 1997. The company has since then continued to operate in Nigeria, manufacturing and distributing “world-class quality pharmaceutical and healthcare products and services that meet customers’ expectations at all times”. It also engages in contract manufacturing as a means of putting its idle plants into good use. It is currently headquartered in Oregun, Lagos.

A look at the company’s segments 

Neimeth’s business is structured into two broad categories: pharmaceutical and veterinary. The pharmaceutical arm is concerned with the production and marketing of the company’s ethical and consumer products, which generate the most revenue. Examples of products manufactured and marketed under the pharmaceutical arm of the company include:

  • Pyrantrin 
  • Pancemol 
  • Nimaterm 
  • Ciklavit 
  • Amlovar
  • Neimelyn 
  • Norduet 
  • Normoretic, etc.

Neimeth’s veterinary business does not currently generate as much revenue for the company. However, information on the company’s website indicate that are plans are in place to revitalise and reposition the segment towards becoming a major money spinner.

Deal book 300 x 250
Sigma Pensions

Some of the products currently manufactured under the veterinary arm include:

  • Neimycin Soluble Powder
  • Neiva Stress
  • Neimeth Piperazine
  • Neimycin Chick Formula

Ownership structure

According to information contained in the company’s full-year 2017 financial report, substantial shareholding is in the following order:

  • Intercedd Health Products Limited: 409,857,176 units of shares which makes up 23.74 percentage.
  • Ordrec Investments Limited: 197,910,746 units of share which makes up 11.46%.
  • Helko Nigeria Limited: 174,466,757; 10.11%.
  • Ohuabunwa S. Iheanyichukwu: 120,681,506 units, making up 6.99%.

The remaining 47.7 share percentage is comprised of indirectly-owned shares by the company’s directors, as well as shares owned by the investing public.

The company’s board of directors

According to information obtained from the company’s website, the board of directors is comprised of ten people, a few of whom are quite prominent including accomplished businessman A.B.C Orjiako, and former INEC Chairman, Professor Maurice Iwu.

Dr Ambrose Bryant Chukwueloka Orjiako is currently the company’s Chairman. The trained medical doctor and oil tycoon joined the company in 2004 and steadily rose through the ranks to his current position.

Stanbic 728 x 90

Dr Orjiako holds major positions in other notable Nigerian companies, including Seplat Petroleum, which is listed on both the Nigerian Stock Exchange and the London Stock Exchange. Nairametrics’ valuation estimates his net worth at over N30 billion.

Another important member of the board is Mr. Christopher U. Umeje, the Acting Managing Director. The trained Accountant and accomplished business professional joined the company in 2008 as an Executive Director. Prior to this time, he had garnered numerous experiences in different industries including banking, manufacturing, and hospitality. He assumed his current position in 2017.

Other notable board members are:

  1. Mrs. Roseline A. Oputa (Executive Director)
  2. Mazi Sam I. Ohuabunwa (Non-Executive Director)
  3. Professor Maurice Iwu (Non-Executive Director)
  4. Engineer Godwin E. Omene (Non-Executive Director)
  5. Mr. A.O. Balogun (Non-Executive Director)
  6. Professor Elijah N. Sokamba (Non-Executive Director)
  7. Thomas Tunbosun Osuku (Non-Executive Director)
  8. Sir Ike Onyechi (Non-Executive Director)

Picture showing percentage shareholdings by the company’s Board of Directors

The company’s target market

As a drug manufacturer, Neimeth International Pharmaceuticals Plc targets patients, drugstores, hospitals, animal breeders, and pet owners in Nigeria and elsewhere in Africa, precisely Anglophone West Africa. Its wide range of remedial medicine is used in hospitals to cure a wide range of ailments, including malaria.

The company is faced with immense competition

Nigeria has a vibrant and highly-competitive pharmaceutical industry, with major players including the likes of Fidson Healthcare Plc and Glaxo Smith Kline Nigeria Plc. These two companies are perhaps the biggest competitive threats faced by Neimeth. For instance, Fidson Healthcare Plc reported a total revenue of N7.4 billion, with a profit after tax of N521 million. Glaxo Smith Kline Plc also reported a revenue of N8.5 billion, with a loss of N103 million. Neimeth, on the other hand, reported a turnover of N877 million and a loss after tax of N29.5 million for the half year ended March 31st, 2018.

Coronation ads

Note that other players in the pharmacy market worth mentioning are Pharma Dekko Plc, May & Baker Plc and Emzor Pharmaceuticals.

A closer look at the company’s financial reports

Neimeth International Pharmaceuticals Plc may run at a loss in 2018 unless some special measures are put in place to mitigate this. This is because so far, the company is already running at a loss. Its 2018 half year result is its worst recorded in the past three years. The company had reported a profit after taxation of N195 million, N100 million, and N181 million for the half-year periods ended March 31st, 2017, 2016, and 2015; respectively.

More on this…

It is unclear what exactly is responsible for Neimeth’s underwhelming performance in H1 2018. Note that the Board gave no explanations regarding this in the unaudited financial result published on the company website. While we anticipate an explanation, it is unlikely that Neimeth International Pharmaceutical Plc will use economic recession and high exchange rates as excuses for their under-performance during this period.

Recall that the company had cited “restricted access to official foreign exchange” as one of the major challenges that adversely affected its business activities in full-year 2017. More so, a fire outbreak on March 7th, 2017 had destroyed the company’s raw material warehouse. This is yet another mitigating factor that contributed to a huge loss of N404.9 million in 2017.


A fire outbreak at the company’s facility in 2017 contributed to the company’s loss

But there has not been a fire outbreak on any of the company’s facilities this year. Moreover, the Nigerian economy has overcome recession, even as the Naira’s exchange rate against the dollar has remained relatively stable for a while now. Therefore, none of these major constraints could possibly have affected the company during the period under consideration.

In conclusion…

Neimeth International Pharmaceuticals Plc should consider tapping into the potentials that abound in its veterinary segment. This potential is currently untapped, despite its existence. Little wonder the segment generated less than 10% of the company’s total revenue for the period under review.

In the meantime, the company needs to improve on its marketing tactics in Nigeria in order to have competitive advantage over the other drug manufacturers. As noted earlier, the competition in this industry is stiff. Hence, marketing must be vigorous.

The company should also strategise and come up with many more workable means of getting ahead. Nigeria has a huge pharmacy market that can be explored further. This is important because the company is vital to the economy and cannot afford to under-perform.

Emmanuel is a professional writer and business journalist, with interests covering Banking & Finance, Mergers and Acquisitions, Corporate Profiles, Brand Communication, Fintech, and MSMEs.He initially joined Nairametrics as an all-round Business Analyst, but later began focusing on and covering the financial services sector. He has also held various leadership roles, including Senior Editor, QAQC Lead, and Deputy Managing Editor.Emmanuel holds an M.Sc in International Relations from the University of Ibadan, graduating with Distinction. He also graduated with a Second Class Honours (Upper Division) from the Department of Philosophy & Logic, University of Ibadan.If you have a scoop for him, you may contact him via his email- [email protected] You may also contact him through various social media platforms, preferably LinkedIn and Twitter.

Click to comment

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.


COVID-19, VAT, FX scarcity adversely impacted our operations in 2020 – Nigerian Breweries boss says

NB Plc’s operations in 2020 were adversely impacted by the COVID-19 pandemic, VAT increase and FX devaluation.



Heineken scoops more Nigerian Breweries shares in insider disclosure

The management of Nigeria’s leading brewer, Nigerian Breweries Plc has revealed that its operations in 2020 were adversely impacted by the COVID-19 pandemic, VAT increase, FX devaluation and scarcity of foreign exchange.

This statement was made by the Managing Director of Nigerian Breweries, Mr Jordi Borrut Bel, at the company’s pre-AGM media briefing for the financial year-end 2020, which held in Lagos this week.

He noted that the increase in the brewer’s cost in 2020 was due to the COVID-19 pandemic which disrupted the company’s operations, as well as the increase in VAT, devaluation and FX scarcity which has put pressure on input cost.

READ: Alcoholic beverage makers on NSE lose a total N27.7 billion in a single day

The Nigerian Breweries boss explained further that the increase in cost could not be fully attributed to currency devaluation and foreign exchange scarcity.

He explained that the increase in costs of goods sold, as reported in its audited financial results, could also be linked to the increase in the volume of goods sold, as the company’s sales volume in 2020 increased by almost the same percentage as the cost of goods sold.

To deal with this challenge going forward, he revealed that the company is focused on the supply chain, and will continue to seek out ways to mitigate any of the price increases coming from FX scarcity.

READ: Brewery sector: A quarter to forget

Deal book 300 x 250
Sigma Pensions

The company’s profitability in question?

An analysis of the company’s result revealed that despite the 4.3% increase in net revenue from N323.00 billion recorded in 2019, to a total of N337.01 billion in 2020, the company’s profit declined significantly by 53.3% to N7.53 billion.

Speaking on this, Jordi Borrut in his statement at the press briefing noted that the brewer’s business performance in 2020 was quite impressive especially in the face of the COVID-19 pandemic and economic recession. Despite these challenges, the company maintained a strong and healthy balance sheet.

There was a slight reduction in profitability but compared to the previous year, the business witnessed an improved growth in revenue. The significance of this is that the business became more stable and healthier,” he said.

READ: Nigeria’s triangular beer war on the rise with the arrival of Budweiser

What you should know

  • Nigerian breweries, being the largest brewer in the country, maintained its stance in terms of generating profits year-on-year. The company emerged as the only brewer to record a profit of N7.37 billion from its operations in 2020, 54.3% lower than 2019 figures (N16.1 billion).
  • From this, the leading brewer was able to pay shareholders a total dividend of N7.5 billion, translating to a dividend of 94 kobos per share – a dividend payout in which exceeds 100%.
  • While Guinness and International Breweries made a loss of N12.6 billion and N24.9 billion respectively, this reality impacted their ability to pay their shareholders dividends in 2020.

Stanbic 728 x 90
Continue Reading

Business News

Highest paid Nigerian bank MD/CEOs of 2020

Bank MD/CEOs in Nigeria earned a combined N1.5 billion in salaries in 2020.



The banking sector, especially commercial banks, is one of the most profitable sectors of the Nigerian Economy churning out profits of close to a trillion in 2020 alone. They are also one of the highest employers of labours in the country employing over 93,000 Nigerians.

Sitting at the helm of affairs is the Chief Executive/Managing Director, the highest-ranking executive in the organization saddled with the responsibility of making the best corporate decisions, oversight of the execution of the organisation’s corporate strategies and most importantly increasing the shareholders’ return. The buck basically stops on their table.

Thus, these enormous responsibilities also come with a considerable executive compensation for their service making them ostensibly the highest-ranking staff of the bank.

READ: Jim Ovia: From a clerk to founder of Nigeria’s most profitable bank

In typical Nairametrics fashion, we bring to you a list of the highest-ranking bank CEOs for 2020 based on their executive compensation (exec comps). The bank MD/CEOs under our review earned over N1.5 billion in salaries in 2020.

The data was sourced from the published audited accounts of the bank and verified by Nairametrics Research.


Deal book 300 x 250
Sigma Pensions

Continue Reading


Nairametrics | Company Earnings

Access our Live Feed portal for the latest company earnings as they drop.